S den Boon1, A Matteelli2, H Getahun2. 1. Independent consultant, Geneva, Switzerland. 2. The Global TB Programme, World Health Organization, Geneva, Switzerland.
Abstract
SETTING: Treatment for latent tuberculous infection (LTBI) reduces the risk of tuberculosis (TB) disease. Shorter, rifamycin-containing regimens have been shown to be as effective as 6 months of isoniazid and superior with regard to safety and completion rate. It is unknown whether preventive therapy with rifamycins increases resistance to the drugs used. OBJECTIVE: To determine whether treatment for LTBI with rifamycin-containing regimens leads to significant development of resistance against rifamycins. DESIGN: Systematic review and meta-analysis. RESULTS: We included six randomised-controlled trials of rifamycin-containing regimens for LTBI treatment that reported drug resistance. There was no statistically significant increased risk of rifamycin resistance after LTBI treatment with rifamycin-containing regimens compared to non-rifamycin-containing regimens (RR 3.45, 95%CI 0.72-16.56; P = 0.12) or placebo (RR 0.20, 95%CI 0.02-1.66; P = 0.13). CONCLUSION: Preventive treatment with rifamycin-containing regimens does not significantly increase rifamycin resistance. Programmatic management of LTBI requires the creation of sound surveillance systems to monitor drug resistance.
SETTING: Treatment for latent tuberculous infection (LTBI) reduces the risk of tuberculosis (TB) disease. Shorter, rifamycin-containing regimens have been shown to be as effective as 6 months of isoniazid and superior with regard to safety and completion rate. It is unknown whether preventive therapy with rifamycins increases resistance to the drugs used. OBJECTIVE: To determine whether treatment for LTBI with rifamycin-containing regimens leads to significant development of resistance against rifamycins. DESIGN: Systematic review and meta-analysis. RESULTS: We included six randomised-controlled trials of rifamycin-containing regimens for LTBI treatment that reported drug resistance. There was no statistically significant increased risk of rifamycin resistance after LTBI treatment with rifamycin-containing regimens compared to non-rifamycin-containing regimens (RR 3.45, 95%CI 0.72-16.56; P = 0.12) or placebo (RR 0.20, 95%CI 0.02-1.66; P = 0.13). CONCLUSION: Preventive treatment with rifamycin-containing regimens does not significantly increase rifamycin resistance. Programmatic management of LTBI requires the creation of sound surveillance systems to monitor drug resistance.
Authors: Haileyesus Getahun; Reuben Granich; Delphine Sculier; Christian Gunneberg; Leopold Blanc; Paul Nunn; Mario Raviglione Journal: AIDS Date: 2010-11 Impact factor: 4.177
Authors: Neil A Martinson; Grace L Barnes; Lawrence H Moulton; Reginah Msandiwa; Harry Hausler; Malathi Ram; James A McIntyre; Glenda E Gray; Richard E Chaisson Journal: N Engl J Med Date: 2011-07-07 Impact factor: 91.245
Authors: F Gordin; R E Chaisson; J P Matts; C Miller; M de Lourdes Garcia; R Hafner; J L Valdespino; J Coberly; M Schechter; A J Klukowicz; M A Barry; R J O'Brien Journal: JAMA Date: 2000-03-15 Impact factor: 56.272
Authors: J L Johnson; A Okwera; D L Hom; H Mayanja; C Mutuluuza Kityo; P Nsubuga; J G Nakibali; A M Loughlin; H Yun; P N Mugyenyi; A Vernon; R D Mugerwa; J J Ellner; C C Whalen Journal: AIDS Date: 2001-11-09 Impact factor: 4.177
Authors: A Matteelli; P Olliaro; L Signorini; G Cadeo; A Scalzini; L Bonazzi; S Caligaris; L Tomasoni; A Tebaldi; G Carosi Journal: Int J Tuberc Lung Dis Date: 1999-11 Impact factor: 2.373
Authors: Kelly Dooley; Charles Flexner; Judith Hackman; Charles A Peloquin; Eric Nuermberger; Richard E Chaisson; Susan E Dorman Journal: Antimicrob Agents Chemother Date: 2008-09-02 Impact factor: 5.191
Authors: Haileyesus Getahun; Alberto Matteelli; Ibrahim Abubakar; Mohamed Abdel Aziz; Annabel Baddeley; Draurio Barreira; Saskia Den Boon; Susana Marta Borroto Gutierrez; Judith Bruchfeld; Erlina Burhan; Solange Cavalcante; Rolando Cedillos; Richard Chaisson; Cynthia Bin-Eng Chee; Lucy Chesire; Elizabeth Corbett; Masoud Dara; Justin Denholm; Gerard de Vries; Dennis Falzon; Nathan Ford; Margaret Gale-Rowe; Chris Gilpin; Enrico Girardi; Un-Yeong Go; Darshini Govindasamy; Alison D Grant; Malgorzata Grzemska; Ross Harris; C Robert Horsburgh; Asker Ismayilov; Ernesto Jaramillo; Sandra Kik; Katharina Kranzer; Christian Lienhardt; Philip LoBue; Knut Lönnroth; Guy Marks; Dick Menzies; Giovanni Battista Migliori; Davide Mosca; Ya Diul Mukadi; Alwyn Mwinga; Lisa Nelson; Nobuyuki Nishikiori; Anouk Oordt-Speets; Molebogeng Xheedha Rangaka; Andreas Reis; Lisa Rotz; Andreas Sandgren; Monica Sañé Schepisi; Holger J Schünemann; Surender Kumar Sharma; Giovanni Sotgiu; Helen R Stagg; Timothy R Sterling; Tamara Tayeb; Mukund Uplekar; Marieke J van der Werf; Wim Vandevelde; Femke van Kessel; Anna van't Hoog; Jay K Varma; Natalia Vezhnina; Constantia Voniatis; Marije Vonk Noordegraaf-Schouten; Diana Weil; Karin Weyer; Robert John Wilkinson; Takashi Yoshiyama; Jean Pierre Zellweger; Mario Raviglione Journal: Eur Respir J Date: 2015-09-24 Impact factor: 16.671
Authors: Andreas Sandgren; Jannigje M Vonk Noordegraaf-Schouten; Anouk M Oordt-Speets; Gerarda B van Kessel; Sake J de Vlas; Marieke J van der Werf Journal: Euro Surveill Date: 2016-08-25
Authors: S Den Boon; C Lienhardt; M Zignol; K Schwartzman; N Arinaminpathy; J R Campbell; P Nahid; M Penazzato; D Menzies; J F Vesga; O Oxlade; G Churchyard; C S Merle; T Kasaeva; D Falzon Journal: Int J Tuberc Lung Dis Date: 2022-04-01 Impact factor: 3.427
Authors: G B Migliori; S J Wu; A Matteelli; D Zenner; D Goletti; S Ahmedov; S Al-Abri; D M Allen; M E Balcells; A L Garcia-Basteiro; E Cambau; R E Chaisson; C B E Chee; M P Dalcolmo; J T Denholm; C Erkens; S Esposito; P Farnia; J S Friedland; S Graham; Y Hamada; A D Harries; A W Kay; A Kritski; S Manga; B J Marais; D Menzies; D Ng; L Petrone; A Rendon; D R Silva; H S Schaaf; A Skrahina; G Sotgiu; G Thwaites; S Tiberi; N Tukvadze; J-P Zellweger; L D Ambrosio; R Centis; C W M Ong Journal: Int J Tuberc Lung Dis Date: 2022-03-01 Impact factor: 3.427